S7771
(S)-(−)-Sulpiride
≥98% (titration)
Synonym(s):
(S)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide, Levosulpiride
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C15H23N3O4S
CAS Number:
Molecular Weight:
341.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (titration)
Quality level:
Quality Level
assay
≥98% (titration)
mp
183-186 °C (lit.)
originator
Sanofi Aventis
storage temp.
2-8°C
SMILES string
CCN1CCC[C@H]1CNC(=O)c2cc(ccc2OC)S(N)(=O)=O
InChI
1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
InChI key
BGRJTUBHPOOWDU-NSHDSACASA-N
Gene Information
human ... DRD2(1813), DRD3(1814)
rat ... Adra1a(29412), Drd2(24318), Drd3(29238), Htr1a(24473), Htr2a(29595)
Application
(S)-(−)-Sulpiride was used to study the effect of dopamine D2 receptor function on activation of KCNQ potassium channels10 and on depression-like behavior in ovariectomized female rats.11
Biochem/physiol Actions
(S)-(−)-Sulpiride or Levosulpiride blocks the inhibitory enteric D2 receptors (neuronal and muscular). It has prokinetic activity and is effective in the treatment of functional dyspepsia and gastroparesis in insulin-dependent diabetes mellitus patients.7,8 Since dopamine controls human sexual function, (S)-(−)-Sulpiride is reportedly effective in treatment of erectile dysfunctions.9
D2 dopamine receptor antagonist; antipsychotic.
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under (S)-(−)-Sulpiride
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Takuya Hikima et al.
Cell reports, 35(1), 108951-108951 (2021-04-08)
Somatodendritic dopamine (DA) release from midbrain DA neurons activates D2 autoreceptors on these cells to regulate their activity. However, the source of autoregulatory DA remains controversial. Here, we test the hypothesis that D2 autoreceptors on a given DA neuron in
P Melga et al.
Diabetes care, 20(1), 55-58 (1997-01-01)
We evaluated the effect of chronic administration of levosulpiride, a prokinetic drug that is a selective antagonist for D2 dopamine receptors, on the glycemic control of IDDM subjects. The study was performed on 40 long-standing IDDM subjects with clinical signs
W Hauber et al.
Behavioural brain research, 106(1-2), 143-150 (1999-12-14)
In the present study, the involvement of dopamine D1 and D2 receptors in the dorsal globus pallidus (GP) in motor control was investigated in rats. Results show that bilateral microinfusions of the dopamine D1 receptor antagonist SCH23390 or the dopamine